Nuvation Bio has presented new pivotal trial data which could give its next-generation ROS1 inhibitor taletrectinib best-in-class status.
But its rival and near-namesake Nuvalent is hot on its heels with a candidate from the same class, zidesamtinib....
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?